Cargando…

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines

The survival rate for osteosarcoma patients with localized disease is 70% and only 25% for patients with metastases. Therefore, novel therapeutic and prognostic tools are needed. In this study, extensive screening and validation strategies identified Axl, EphB2, FGFR2, IGF-1R and Ret as specific rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rettew, A N, Young, E D, Lev, D C, Kleinerman, E S, Abdul-Karim, F W, Getty, P J, Greenfield, E M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511679/ https://www.ncbi.nlm.nih.gov/pubmed/23552467 http://dx.doi.org/10.1038/oncsis.2012.34

Ejemplares similares

Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene
por: Messerschmitt, Patrick J., et al.
Publicado: (2012)

Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions
por: Wolf-Dennen, Kerri, et al.
Publicado: (2020)

Osteosarcoma Overview
por: Lindsey, Brock A., et al.
Publicado: (2016)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
por: Assi, Ahmad, et al.
Publicado: (2023)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
por: Tian, Zhichao, et al.
Publicado: (2020)

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines
por: Fenger, Joelle M., et al.
Publicado: (2016)

Cellular and Phenotypic Characterization of Canine Osteosarcoma Cell Lines
por: Legare, Marie E., et al.
Publicado: (2011)

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
por: Chen, Chenglong, et al.
Publicado: (2022)

Epigenetic Regulation of Apoptosis and Cell Cycle in Osteosarcoma
por: Rao-Bindal, Krithi, et al.
Publicado: (2011)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
por: Teishima, Jun, et al.
Publicado: (2021)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
por: Elloumi-Mseddi, Jihene, et al.
Publicado: (2013)

Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer
por: Bulk, Etmar, et al.
Publicado: (2012)

Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2017)

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts
por: Rao-Bindal, K, et al.
Publicado: (2012)

Characterization of the metastatic phenotype of a panel of established osteosarcoma cells
por: Ren, Ling, et al.
Publicado: (2015)

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
por: Poddubskaya, Elena V., et al.
Publicado: (2018)

Multiple Effects of Resveratrol on Osteosarcoma Cell Lines
por: De Luca, Angela, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma
por: Crusz, Shanthini M., et al.
Publicado: (2016)

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
por: Ishihara, Hiroki, et al.
Publicado: (2017)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Establishment and characterization of a highly metastatic human osteosarcoma cell line from osteosarcoma lung metastases
por: Fan, Zepei, et al.
Publicado: (2021)

The Orphan Tyrosine Kinase Receptor, ROR2, Mediates Wnt5A Signaling in Metastatic Melanoma
por: O’Connell, Michael P., et al.
Publicado: (2009)

The relationship between metastatic potential and in vitro mechanical properties of osteosarcoma cells
por: Holenstein, Claude N., et al.
Publicado: (2019)

Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
por: Udupa, Karthik S, et al.
Publicado: (2017)

Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
por: Luttman, Jillian Hattaway, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Exosome‐transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma
por: Li, Qiming, et al.
Publicado: (2020)

Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
por: Park, Tae Ju, et al.
Publicado: (2016)

Combination of NK cells therapy and oral administration of entinostat as an approach for osteosarcoma lung metastasis treatment
por: Kiany, Simin, et al.
Publicado: (2015)

Single‐Center Experience with Ifosfamide Monotherapy as Second‐Line Treatment of Recurrent/Metastatic Osteosarcoma
por: Verschoor, Arie Jan, et al.
Publicado: (2019)

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
por: Yang, Yuanzheng, et al.
Publicado: (2022)

Association of Canine Osteosarcoma and Monocyte Phenotype and Chemotactic Function
por: Tuohy, J.L., et al.
Publicado: (2016)

Flavokawain B induced cytotoxicity in two breast cancer cell lines, MCF-7 and MDA-MB231 and inhibited the metastatic potential of MDA-MB231 via the regulation of several tyrosine kinases In vitro
por: Abu, Nadiah, et al.
Publicado: (2016)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_2jqobrgrmt9oi258sid7jui895